Corcept Therapeutics Incorporated (FRA:HTD)

Market Cap	3.11B -54.8%
Revenue (ttm)	631.70M +17.9%
Net Income	89.20M -25.2%
EPS	0.74 -30.7%
Shares Out	n/a
PE Ratio	34.85
Forward PE	61.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60
Average Volume	3
Open	28.79
Previous Close	33.40
Day's Range	28.79 - 29.42
52-Week Range	28.79 - 105.30
Beta	n/a
RSI	29.03
Earnings Date	Feb 18, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HTD

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD